Analysis of industry assets newly into human trials reveals three Car-T therapies and some familiar targets.

The group highlights safety and manufacturability, as well as efficacy, but investors apparently have doubts.

But the FDA’s investigation looks like worse news for autoimmune disease than oncology.

The new deal comes as Carvykti manufacturing problems continue and 2seventy dials down Abecma expectations.

Novartis and Gracell place further bets on shortened production times, with Bristol waiting in the wings.

Arcellx climbs 19%, but the most significant Car-T presentation at ASH might not even be in oncology.

But late-breaking data raise questions about lack of a dose response.

The big pharma group had two anti-BCMA assets to choose from, and yesterday gave Harpoon the bad news.